Send feedback

ELAC2 p.Ala652Val

c.1955C>T · rs761881914 · VCV1432888

Uncertain significance Multiple submitters
Classification
Uncertain significance
ClinVar
Review
Multiple submitters ★★☆☆
ClinVar · 2 submitters
AlphaMissense
likely benign
0.1503 · ACMG-weighted
gnomAD v4.1
Rare
very rare (popmax 0.00768%, sas)
Missense predictors
0/3 damaging
AlphaMissense, REVEL, SaProt
Conditions
1
combined oxidative phosphorylation defect type 17

Computational evidence

Protein change
AlphaMissense0.1503likely benign
REVEL0.146moderately benign-leaning
SaProtLLR -7.54tolerated
⇒ AlphaMissense, REVEL and SaProt all call this tolerated.
Splicing
SpliceAI—not assessed · no allele here is in the release
Constraint at this position
ConservationphyloP 9.9GERP 2.1, phastCons 1
Regional constrainto/e 1.03unconstrained · MANE · 25 kb · p 0.4 · regional, not allelic
Overall
CADD25.7PHRED · no single calibrated threshold — expert panels disagree

ClinVar classifies this uncertain; the computational predictors unanimously lean tolerated — a triage signal, not a reclassification

AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.

Population frequency

gnomAD v4.1 · exomes + genomes
Grpmax group 0.00768% South Asian · 7/91,088 alleles
Filtering AF 0.00359% ClinGen BA1/BS1 input FAF95, joint · FAF99 0.00255%
Overall 0.00613% 99/1,613,894 alleles · very rare
Ancestry group Frequency 1 in
Finnishnot grpmax-eligible 0.0611% 1,637
Remaining individualsnot grpmax-eligible 0.0128% 7,810
South Asiangrpmax 0.00768% 13,013
African / African-American 0.00534% 18,732
European (non-Finnish) 0.00347% 28,781

Finnish shows a higher raw frequency than the grpmax group above it. gnomAD excludes bottlenecked groups — Finnish, Ashkenazi Jewish, Amish and “Remaining individuals” — from grpmax, because founder effects make their frequencies unrepresentative for filtering. The table is sorted by frequency, so an excluded group can sit above the grpmax row.

Rarity supports pathogenicity (ACMG PM2); frequency above a disease-specific BA1/BS1 threshold argues against it. A variant frequent in one ancestry group can be near-absent in others, so a single global figure can mislead.

Variant & gene context

Gene
ELAC2
Protein
p.Ala652Val
Coding
c.1955C>T
MANE Select
NM_018127
dbSNP
rs761881914
Type
single nucleotide variant
Location
chr17:12994838 (GRCh38)
Gene constraint
LOEUF 1.02 · pLI <0.01 (gnomAD)
Structure
AlphaFold pLDDT 82.81 · 10 PDB
Residue 652
a β-strand
Full ELAC2 gene report on Sugi Atlas → Gene function, pathways, protein structure, interactions & more

Disease context

combined oxidative phosphorylation defect type 17 — disease report on Sugi Atlas → Associated genes, phenotypes, clinical trials & treatments

For Combined oxidative phosphorylation defect type 17 (Orphanet):

Inheritance
Autosomal recessive
Onset
Infancy, Neonatal

Similar variants

Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →

Cite Sugi Variant

Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/elac2-p-ala652val (accessed [today's date]).

Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown